BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 26, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» CTX-10726 bispecific antibody shows robust preclinical efficacy
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
CTX-10726 bispecific antibody shows robust preclinical efficacy
Nov. 26, 2025
No Comments
Researchers from Compass Therapeutics Inc. detailed the preclinical characterization of CTX-10726, a bispecific, tetravalent antibody that simultaneously targets VEGF-A and PD-1.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Bispecific antibody
Immuno-oncology
